By David Douglas NEW YORK (Reuters Health) – Mammalian target of rapamycin (mTOR) inhibitor treatment has been linked with acute tubular necrosis (ATN) in four case reports from…
NEW YORK (Reuters Health) – A small study indicates that most patients with cutaneous B-cell lymphoma who respond well to rituximab relapse after about two years. On the…
NEW YORK (Reuters Health) – Contrary to a historically pessimistic outlook, high-risk prostate cancer can be controlled with moderate high-dose radiation treatment and prolonged androgen-deprivation therapy (ADT). That…
By Will Boggs, MD NEW YORK (Reuters Health) – Carboplatin plus pemetrexed improves survival over pemetrexed alone in ambulatory patients with advanced non-small-cell lung cancer (NSCLC), randomized trial…
NEW YORK (Reuters Health) – An updated meta-analysis supports the strategy of giving intravesical chemotherapy (IVC) immediately after bladder tumor resection to reduce the risk of recurrence. “However,…
NEW YORK (Reuters Health) – The cumulative incidence of osteonecrosis of the jaw was about 2% over 6 years among women with early breast cancer who received intensive…
NEW YORK (Reuters Health) – Morbidity associated with inguinal lymphadenectomy in patients with penile carcinoma has declined, and is “reasonable” considering the potential benefit, a Brazilian team reports.…
By David Douglas NEW YORK (Reuters Health) – Dual HER2 blockade didn’t increase heart problems in a meta-analysis of data from patients with HER2-positive breast cancer. “The combination…
NEW YORK (Reuters Health) – For patients with head and neck or esophageal cancer undergoing chemoradiotherapy, enteral nutrition enriched with n-3 fatty acids helps preserve body mass. The…
By Will Boggs, MD NEW YORK (Reuters Health) – Hormone therapy may suffice for women with stage IA endometrial cancer of all grades, if they want to try…